AFRRI and Cleveland BioLabs (CBLI) Awarded $612K Grant
More News related to CBLI
- Cleveland BioLabs (CBLI) Gets Patent for Radiation Protection, Including Protectan CBLB502
- Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
- Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
- Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
- Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that the Joint Science and Technology Office for Chemical and Biological Defense at the Defense Threat Reduction Agency of the Department of Defense awarded the Armed Forces Radiobiology Research Institute (AFRRI) a $612,000 grant to study, with technical assistance from the Company, select compounds within Cleveland BioLabs's Protectan 600 series for development as a radiation countermeasure for treatment of acute radiation syndrome.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
